Trial to Assess Chelation Therapy (TACT)

NCT ID: NCT00044213

Last Updated: 2013-11-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1708 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

EDTA chelation therapy involves repeated administrations of a synthetic amino acid to reduce atherosclerotic plaque and other mineral deposits throughout the cardiovascular system.

Participants will be randomly assigned to receive 40 infusions of either the standard chelation solution or placebo. The primary endpoint of this trial will be a composite of all cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina.

The results of TACT will provide either a significant positive result or an informative null result upon which rational clinical decision-making and health policy can be based.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EDTA + high dose vitamin

Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.

Group Type ACTIVE_COMPARATOR

EDTA

Intervention Type DRUG

Participants will receive 40 infusions of standard chelation solution.

High Dose Vitamin

Intervention Type DIETARY_SUPPLEMENT

EDTA + high dose vitamin placebo

Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.

Group Type PLACEBO_COMPARATOR

EDTA

Intervention Type DRUG

Participants will receive 40 infusions of standard chelation solution.

High Dose Vitamin Placebo

Intervention Type DIETARY_SUPPLEMENT

EDTA placebo + high dose vitamin

Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.

Group Type PLACEBO_COMPARATOR

EDTA Placebo

Intervention Type DRUG

Participants will receive 40 infusions of EDTA placebo.

High Dose Vitamin

Intervention Type DIETARY_SUPPLEMENT

EDTA placebo + high dose vitamin placebo

Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Group Type PLACEBO_COMPARATOR

EDTA Placebo

Intervention Type DRUG

Participants will receive 40 infusions of EDTA placebo.

High Dose Vitamin Placebo

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EDTA

Participants will receive 40 infusions of standard chelation solution.

Intervention Type DRUG

EDTA Placebo

Participants will receive 40 infusions of EDTA placebo.

Intervention Type DRUG

High Dose Vitamin

Intervention Type DIETARY_SUPPLEMENT

High Dose Vitamin Placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Heart attack at least 6 weeks prior to study start

Exclusion Criteria

* Serum creatinie level greater than 2.0 mg/dL
* Platelet count less than 100,000/µL
* Blood pressure greater than 160/100
* Chelation therapy within 5 years prior to study start
* History of allergic reactions to EDTA or any of the therapy's components
* Coronary or carotid revascularization procedures within 6 months prior to study start or a scheduled revascularization
* Cigarette smoking within 3 months prior to study start
* Childbearing potential
* History of liver disease
* Active heart failure or heart failure hospitalization within 6 months.
* Diagnoses of additional medical conditions that could otherwise limit patient survival
* Inability to tolerate 500-mL infusions weekly.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

Sponsor Role collaborator

Mt. Sinai Medical Center, Miami

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gervasio Lamas, MD

Chair, Department of Medicine- Chief, Division of Cardiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gervasio A Lamas, M.D.

Role: STUDY_DIRECTOR

Icahn School of Medicine at Mount Sinai

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Arkansas Veterans Healthcare System

Little Rock, Arkansas, United States

Site Status

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

Mt Holistic Health Center

Danville, California, United States

Site Status

Patrick A. Golden

Fresno, California, United States

Site Status

Scripps Center for Integrative Medicine

La Jolla, California, United States

Site Status

Phoenix Wellness Group

Napa, California, United States

Site Status

Aurora Denver Cardiology Associates

Denver, Colorado, United States

Site Status

The Blend Institute

Bradenton, Florida, United States

Site Status

Wellness Works

Brandon, Florida, United States

Site Status

Innovative Research of West Florida

Clearwater, Florida, United States

Site Status

Hyperbaric Medicine Inc.

Fort Walton Beach, Florida, United States

Site Status

White-Wilson Medical Center

Fort Walton Beach, Florida, United States

Site Status

Tru Med

Melbourne, Florida, United States

Site Status

Baptist Cardiac & Vascular Institute

Miami, Florida, United States

Site Status

Mount Sinai Medical Center

Miami Beach, Florida, United States

Site Status

Tri-Health Alternative Medical Center

Mt. Dora, Florida, United States

Site Status

Heart and Vascular Center for Research, Inc.

Sarasota, Florida, United States

Site Status

Florida Cardiovascular Institute

Tampa, Florida, United States

Site Status

Life Family Practice Center for Complementary and Alternative Medicine

The Villages, Florida, United States

Site Status

Florida Medical Clinic, P.A. Clinical Research Division

Zephyrhills, Florida, United States

Site Status

Emory University School of Medicine

Atlanta, Georgia, United States

Site Status

Full Circle Medical Center

Fort Oglethorpe, Georgia, United States

Site Status

Crossroads Healing Arts LLC

Goshen, Indiana, United States

Site Status

Integrative Medical Center at Schneck Medical Center

Seymour, Indiana, United States

Site Status

Northwest Indiana Cardiovascular Physicians Inc.

Valparaiso, Indiana, United States

Site Status

Kansas University Medical Center

Kansas City, Kansas, United States

Site Status

The Center for the Improvement of Functioning International

Wichita, Kansas, United States

Site Status

Complementary Medical Services

Mandeville, Louisiana, United States

Site Status

Maine Integrative Wellness

Portland, Maine, United States

Site Status

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Site Status

Marino Center for Progressive Health

Cambridge, Massachusetts, United States

Site Status

Henry Ford Health System Preventative Cardiology Clay Ford Center for Athletic Medicine

Detroit, Michigan, United States

Site Status

The Preventive Medicine Center

Flint, Michigan, United States

Site Status

Born Preventive Health Care Clinic

Grand Rapids, Michigan, United States

Site Status

Parchment Family Practice

Kalamazoo, Michigan, United States

Site Status

Berman Center for Outcomes and Clinical Research

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic and Foundation Cardiovascular Health Clinic

Rochester, Minnesota, United States

Site Status

University of Missouri Hospital and Clinics

Columbia, Missouri, United States

Site Status

Brian Dieterle, MD, PhD

Hollister, Missouri, United States

Site Status

Preventive Medicine

St Louis, Missouri, United States

Site Status

Deborah Heart and Lung Center

Browns Mills, New Jersey, United States

Site Status

Magaziner Center for Wellness

Cherry Hill, New Jersey, United States

Site Status

Park Professional Building

Roselle Park, New Jersey, United States

Site Status

Stockton Family Practice

Stockton, New Jersey, United States

Site Status

Heart Care Center

East Syracuse, New York, United States

Site Status

The Gables Natural Medicines Center & Day Spa Family Health Services

Mayville, New York, United States

Site Status

NYU School of Medicine

New York, New York, United States

Site Status

Rhinebeck Health Center

Rhinebeck, New York, United States

Site Status

Staten Island Heart

Staten Island, New York, United States

Site Status

Schachter Center for Complementary Medicine

Suffern, New York, United States

Site Status

Bronx-Lebanon Hospital Center

The Bronx, New York, United States

Site Status

Integrative Medical Associates, PLLC

Tryon, North Carolina, United States

Site Status

Celebration of Health Center

Bluffton, Ohio, United States

Site Status

University Hospitals of Cleveland

Cleveland, Ohio, United States

Site Status

The Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Comprehensive Heart Care, Inc.

Toledo, Ohio, United States

Site Status

Upper Valley Family Care

Troy, Ohio, United States

Site Status

COR Research

Oklahoma City, Oklahoma, United States

Site Status

St. Charles Health System

Bend, Oregon, United States

Site Status

Center for Environmental Medicine

Portland, Oregon, United States

Site Status

Wholistic Health Center

Greensburg, Pennsylvania, United States

Site Status

Woodlands Healing Research Center

Quakertown, Pennsylvania, United States

Site Status

Main Line Health Heart Center

Wynnewood, Pennsylvania, United States

Site Status

Biogenesis Medical Center

Landrum, South Carolina, United States

Site Status

Athens Surgery Clinic

Athens, Tennessee, United States

Site Status

The Castle Clinic, PLLC

Johnson City, Tennessee, United States

Site Status

Chelation Centers of Texas

Texas City, Texas, United States

Site Status

Freedom Center for Advanced Medicine

Provo, Utah, United States

Site Status

The Cardiovascular Group

Fairfax, Virginia, United States

Site Status

Virginia Beach General Hospital

Virginia Beach, Virginia, United States

Site Status

Hope Medical Holistic Clinic

Vancouver, Washington, United States

Site Status

Care Foundation Inc.

Wausau, Wisconsin, United States

Site Status

Waters Preventive Medical Center, LTD

Wisconsin Dells, Wisconsin, United States

Site Status

Cline Medical Centre

Nanaimo, British Columbia, Canada

Site Status

The Wellness Centre

Port Hawkesbury, Nova Scotia, Canada

Site Status

Chelation Center of Barrie, Inc.

Barrie, Ontario, Canada

Site Status

Anti-Aging & Family Wellness Clinic

Madoc, Ontario, Canada

Site Status

Markham Integrative Medicine

Markham, Ontario, Canada

Site Status

North Bay Complementary

North Bay, Ontario, Canada

Site Status

Seekers Centre for Integrative Medicine

Ottawa, Ontario, Canada

Site Status

Dr. C. Minielly

Smith Falls, Ontario, Canada

Site Status

Chelation Center of Don Valley Inc.

Toronto, Ontario, Canada

Site Status

Jaconello Health Centre

Toronto, Ontario, Canada

Site Status

Chelation and Natural Therapy

Toronto, Ontario, Canada

Site Status

Chelox

Toronto, Ontario, Canada

Site Status

Saskatoon Chelation Centre

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Escolar E, Ujueta F, Kim H, Mark DB, Boineau R, Nahin RL, Goertz C, Lee KL, Anstrom KJ, Lamas GA. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). J Diabetes Complications. 2020 Aug;34(8):107616. doi: 10.1016/j.jdiacomp.2020.107616. Epub 2020 May 7.

Reference Type DERIVED
PMID: 32446881 (View on PubMed)

Mark DB, Anstrom KJ, Clapp-Channing NE, Knight JD, Boineau R, Goertz C, Rozema TC, Liu DM, Nahin RL, Rosenberg Y, Drisko J, Lee KL, Lamas GA; TACT Investigators. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial. Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):508-16. doi: 10.1161/CIRCOUTCOMES.114.000977.

Reference Type DERIVED
PMID: 24987051 (View on PubMed)

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT (Trial to Assess Chelation Therapy) Investigators. Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med. 2013 Dec 17;159(12):797-805. doi: 10.7326/0003-4819-159-12-201312170-00004.

Reference Type DERIVED
PMID: 24490264 (View on PubMed)

Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15-24. doi: 10.1161/CIRCOUTCOMES.113.000663. Epub 2013 Nov 19.

Reference Type DERIVED
PMID: 24254885 (View on PubMed)

Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107.

Reference Type DERIVED
PMID: 23532240 (View on PubMed)

Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002.

Reference Type DERIVED
PMID: 22172430 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U01HL092607

Identifier Type: NIH

Identifier Source: secondary_id

View Link

U01AT001156

Identifier Type: NIH

Identifier Source: secondary_id

View Link

654

Identifier Type: -

Identifier Source: org_study_id